With PSMA radioligand therapy, nuclear medicine offers a promising, non-invasive procedure for diagnosing and treating prostate cancer, that has hardly any side effects and a life-prolonging effect even in the final stages while maintaining a good quality of life.
EANM and SNMMI have updated their joint PSMA PET/CT procedure guideline for prostate cancer imaging with the most recent information. “This guideline supports physicians in recommending, acquiring, interpreting and reporting the results of PSMA-ligand PET/CT for initial diagnosis, staging and restaging of prostate cancer. … This document reports on patient selection, PET/CT acquisition, image interpretation and written summary of the clinical report. Specific advice is given for the most common PSMA radioligands available and for clinical scenarios with frequent use of PET/CT, including staging, restaging and assessment for suitability of PSMA RLT.”
Die Zukunft hat begonnen. Therapie auf dem nächsten Level.
The future has started. Experience therapy on the next level.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. The cookies categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. Read our full Cookie Policy.
Therapie der Zukunft: we fight your cancer
